TY - JOUR T1 - The role of cathepsin S in the development of inflammation in patients with severe bronchial asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3106 VL - 58 IS - suppl 65 SP - PA3106 AU - Angelina Kraposhina AU - Irina Demko AU - Elena Sobko AU - Natalia Gordeeva AU - Irina Soloveva AU - Marina Mamaeva Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3106.abstract N2 - Goal: To determine the relationship of cathepsin S level with clinical and functional indicators in patients with severe bronchial asthma.Materials and methods: 109 patients with severe bronchial asthma of women were examined - 84 (77.1%), men - 35 (22.9%), which were divided into 2 groups: 84 people with allergic severe bronchial asthma and 25 with non-allergic severe bronchial asthma. Study of external respiration function was done with whole-body plethysmography ("Erich Eger”, Germany). The concentration of cytokines IL-4, IL-5, IL-13, periostine, cathepsin S, TGF-β in blood plasma was determined with ELISA (eBioscience, USA).Results: Patients with severe bronchial asthma are characterized by an uncontrolled course of the disease. In both allergic and non-allergic severe bronchial asthma, fixed obstruction is recorded in 64% and 68% of cases, respectively. Peripheral blood eosinophilia occurs in 28.5% of cases with allergic and in 16% of cases with non-allergic severe bronchial asthma. In both groups there is an increase in the plasma content of IL-4, IL-13, periostin, TGF-β and cathepsin S. Cathepsin S is in positive correlation with clinical symptoms of the disease and concentration of IL-4, IL-5, IL-13 in allergic severe bronchial asthma. A positive correlation was established between the level of cathepsin S and TGF-β in both groups.Conclusion: The revealed positive correlation between cathepsin S and TGF-β levels may indirectly indicate cathepsin S involvement in airway remodeling processes.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3106.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -